Research On The Motivation And Effect Of Innovent Biologics’s Introduction Of Venture Capital

The upper reaches of the biopharmaceutical industry chain are generally research work,which is usually done by independent medical laboratories,and some hospitals also open specialized laboratories to carry out research work on some outsourced projects.The midstream of the industrial chain is basically occupied by biopharmaceutical enterprises,the production includes all kinds of vaccines,antibody reagents and other products,downstream is mainly to carry out product sales,pharmaceutical products will be through physical pharmacies or e-commerce and other ways to reach the hands of consumers.In recent years,the development of biopharmaceuticals is extremely rapid,the United States as the birthplace of the industry,in the world’s leading position,Germany,France and other European countries,although the overall level of the United States has a gap,but also have their own good and outstanding areas.Domestic biopharmaceutical industry started and developed in the 1980 s,the biopharmaceutical industry is currently in the stage of explosive growth,there are a number of strong enterprises successfully IPO and in the continuous competition to seize the domestic market,there are still a large number of biopharmaceutical start-ups are lack of funds,industry line shortage and other difficult conditions.Cinda Bio,as a company that has successfully accepted multiple rounds of venture capital and IPO in a relatively short period of time,has its own unique experience in introducing venture capital.Based on the case of the introduction of venture capital by Cinda Bio,this paper introduces the whole process of Cinda Bio’s introduction of venture capital by means of literature analysis and case analysis,analyzes the advantages of the enterprise itself and the motivation of the introduction of venture capital,and further studies the impact of the introduction of venture capital on the technological innovation,corporate governance,listing and development of enterprises.Based on the analysis of the case of the introduction of venture capital by Cinda Bio,the following conclusions are drawn.First,enterprises and venture capital institutions should do double selection,venture capital institutions will conduct due diligence on enterprises,enterprises should also be based on their own development conditions reasonable choice of venture capital institutions,and ultimately achieve winwin cooperation.Second,enterprises should make effective use of the value-added value brought about by venture capital institutions to achieve technological innovation.Third,good at using venture capital to enhance the company’s governance ability and governance effectiveness,reasonable grasp of the pace of financing,alert to the risk of excessive decentralization of control.Fourth,choose the right listing opportunity,use venture capital to achieve smooth listing and development.This paper hopes to provide many biopharmaceutical start-ups in China with some experience and enlightenment that can realize the development of enterprises by means of venture capital.